Cargando…

ABI3BP is a prognosis biomarker related with clinicopathological features and immunity infiltration of lung tumor

Background: The primary factor of cancer mortality is lung tumor. ABI3BP gene encodes an extracellular matrix bind protein associated to multiplication and derivation. However, the prognosis score of ABI3BP for lung tumor and its relation with immunity cellular infiltration for lung tumor have not b...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Yan, Han, Xiaolei, Zhang, Zhe, Qiao, Han, Tang, Huaping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894588/
https://www.ncbi.nlm.nih.gov/pubmed/36744181
http://dx.doi.org/10.3389/fgene.2022.1085785
_version_ 1784881773536083968
author Feng, Yan
Han, Xiaolei
Zhang, Zhe
Qiao, Han
Tang, Huaping
author_facet Feng, Yan
Han, Xiaolei
Zhang, Zhe
Qiao, Han
Tang, Huaping
author_sort Feng, Yan
collection PubMed
description Background: The primary factor of cancer mortality is lung tumor. ABI3BP gene encodes an extracellular matrix bind protein associated to multiplication and derivation. However, the prognosis score of ABI3BP for lung tumor and its relation with immunity cellular infiltration for lung tumor have not been reported. Methods: Public repository systems (Timer, GEPIA, TCGA, HPA) were utilized to explore expression of ABI3BP for lung tumor, and explored the relation of ABI3BP and clinicopathological parameters. TCGA information set was utilized for cox analysis for data with one or more variables of ABI3BP for lung tumor. STRING was utilized to explore ABI3BP regulatory networks. GO/KEGG enrichment analysis as well as enrichment analysis of gene sets were carried out for ABI3BP co-expression via R package. And finally we explored the relation of expression of ABI3BP and lung tumor immunity invasion, exploring the influence of ABI3BP level of expression on immunotreatment and whether immunity invasion would affect the prognosis of patients with lung tumor. Results: ABI3BP is downregulated in LUAD and LUSC, and associated to lung tumor phase and prognosis. Univariate and multivariate cox regression showed that ABI3BP was an independent prognostic factor in patients with lung tumors. The extracellular matrix protein-coding gene and the ABI3BP-related gene were intersected to obtain 10 hub genes. On the basis of GO/KEGG enrichment analysis, hub genes are closely associated to immunity-associated pathways including T cell receptor signaling pathway, immune response−activating cell surface receptor signaling pathway. Finally, the expression of ABI3BP is closely related to immune cell infiltration and immune cell marker set, and the expression of ABI3BP can help predict the therapeutic effect of immune checkpoint inhibitors and improve the prognosis of patients. Conclusion: ABI3BP could be a new target for lung tumor that could be utilized as a diagnostic and therapeutic tool.
format Online
Article
Text
id pubmed-9894588
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98945882023-02-03 ABI3BP is a prognosis biomarker related with clinicopathological features and immunity infiltration of lung tumor Feng, Yan Han, Xiaolei Zhang, Zhe Qiao, Han Tang, Huaping Front Genet Genetics Background: The primary factor of cancer mortality is lung tumor. ABI3BP gene encodes an extracellular matrix bind protein associated to multiplication and derivation. However, the prognosis score of ABI3BP for lung tumor and its relation with immunity cellular infiltration for lung tumor have not been reported. Methods: Public repository systems (Timer, GEPIA, TCGA, HPA) were utilized to explore expression of ABI3BP for lung tumor, and explored the relation of ABI3BP and clinicopathological parameters. TCGA information set was utilized for cox analysis for data with one or more variables of ABI3BP for lung tumor. STRING was utilized to explore ABI3BP regulatory networks. GO/KEGG enrichment analysis as well as enrichment analysis of gene sets were carried out for ABI3BP co-expression via R package. And finally we explored the relation of expression of ABI3BP and lung tumor immunity invasion, exploring the influence of ABI3BP level of expression on immunotreatment and whether immunity invasion would affect the prognosis of patients with lung tumor. Results: ABI3BP is downregulated in LUAD and LUSC, and associated to lung tumor phase and prognosis. Univariate and multivariate cox regression showed that ABI3BP was an independent prognostic factor in patients with lung tumors. The extracellular matrix protein-coding gene and the ABI3BP-related gene were intersected to obtain 10 hub genes. On the basis of GO/KEGG enrichment analysis, hub genes are closely associated to immunity-associated pathways including T cell receptor signaling pathway, immune response−activating cell surface receptor signaling pathway. Finally, the expression of ABI3BP is closely related to immune cell infiltration and immune cell marker set, and the expression of ABI3BP can help predict the therapeutic effect of immune checkpoint inhibitors and improve the prognosis of patients. Conclusion: ABI3BP could be a new target for lung tumor that could be utilized as a diagnostic and therapeutic tool. Frontiers Media S.A. 2023-01-19 /pmc/articles/PMC9894588/ /pubmed/36744181 http://dx.doi.org/10.3389/fgene.2022.1085785 Text en Copyright © 2023 Feng, Han, Zhang, Qiao and Tang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Feng, Yan
Han, Xiaolei
Zhang, Zhe
Qiao, Han
Tang, Huaping
ABI3BP is a prognosis biomarker related with clinicopathological features and immunity infiltration of lung tumor
title ABI3BP is a prognosis biomarker related with clinicopathological features and immunity infiltration of lung tumor
title_full ABI3BP is a prognosis biomarker related with clinicopathological features and immunity infiltration of lung tumor
title_fullStr ABI3BP is a prognosis biomarker related with clinicopathological features and immunity infiltration of lung tumor
title_full_unstemmed ABI3BP is a prognosis biomarker related with clinicopathological features and immunity infiltration of lung tumor
title_short ABI3BP is a prognosis biomarker related with clinicopathological features and immunity infiltration of lung tumor
title_sort abi3bp is a prognosis biomarker related with clinicopathological features and immunity infiltration of lung tumor
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894588/
https://www.ncbi.nlm.nih.gov/pubmed/36744181
http://dx.doi.org/10.3389/fgene.2022.1085785
work_keys_str_mv AT fengyan abi3bpisaprognosisbiomarkerrelatedwithclinicopathologicalfeaturesandimmunityinfiltrationoflungtumor
AT hanxiaolei abi3bpisaprognosisbiomarkerrelatedwithclinicopathologicalfeaturesandimmunityinfiltrationoflungtumor
AT zhangzhe abi3bpisaprognosisbiomarkerrelatedwithclinicopathologicalfeaturesandimmunityinfiltrationoflungtumor
AT qiaohan abi3bpisaprognosisbiomarkerrelatedwithclinicopathologicalfeaturesandimmunityinfiltrationoflungtumor
AT tanghuaping abi3bpisaprognosisbiomarkerrelatedwithclinicopathologicalfeaturesandimmunityinfiltrationoflungtumor